These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 7224706)

  • 21. The effect of ageing on the hepatic clearance of propranolol.
    Castleden CM; George CF
    Br J Clin Pharmacol; 1979 Jan; 7(1):49-54. PubMed ID: 760742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of gastrointestinal metabolism of propranolol in dogs after portacaval transposition.
    Lo MW; Effeney DJ; Pond SM; Silber BM; Riegelman S
    J Pharmacol Exp Ther; 1982 May; 221(2):512-5. PubMed ID: 7077541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absorption kinetics of sublingually administered propranolol.
    Kates RE
    J Med; 1977; 8(6):393-402. PubMed ID: 272433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.
    Karim A; Kook C; Novotney RL; Zagarella J; Campion J
    Drug Metab Dispos; 1978; 6(3):338-45. PubMed ID: 26556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of propranolol during pregnancy.
    O'Hare MF; Kinney CD; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1984; 27(5):583-7. PubMed ID: 6519163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereochemistry of the in vivo disposition and metabolism of propranolol in dog and man using deuterium-labeled pseudoracemates.
    Walle T
    Drug Metab Dispos; 1985; 13(3):279-82. PubMed ID: 2861983
    [No Abstract]   [Full Text] [Related]  

  • 27. Phencyclidine (PCP) disposition kinetics in dogs as a function of dose and route of administration.
    Woodworth JR; Owens SM; Mayersohn M
    J Pharmacol Exp Ther; 1985 Sep; 234(3):654-61. PubMed ID: 4032285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of diltiazem on the disposition and metabolism of the enantiomers of propranolol in the dog during multiple oral dosing.
    Lankford SM; Maskasame C; Bai SA
    Drug Metab Dispos; 1994; 22(5):776-87. PubMed ID: 7835231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of N-nitrosodimethylamine in beagles.
    Gombar CT; Pylypiw HM; Harrington GW
    Cancer Res; 1987 Jan; 47(2):343-7. PubMed ID: 3791224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.
    Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR
    Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disposition of salmeterol xinafoate in laboratory animals and humans.
    Manchee GR; Barrow A; Kulkarni S; Palmer E; Oxford J; Colthup PV; Maconochie JG; Tarbit MH
    Drug Metab Dispos; 1993; 21(6):1022-8. PubMed ID: 7905380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of bromhexine in the dog.
    Vandecasteele-Thienpont LM; Belpaire FM; Braeckman RA; De Leenheer AP
    Arzneimittelforschung; 1980; 30(10):1643-5. PubMed ID: 7192102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacokinetics of propranolol.
    Routledge PA; Shand DG
    Clin Pharmacokinet; 1979; 4(2):73-90. PubMed ID: 378502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of l-propranolol during repetitive dosing in normal and uranyl nitrate-induced renal failure rats.
    Terao N; Shen DD
    J Pharmacokinet Biopharm; 1984 Oct; 12(5):479-93. PubMed ID: 6520744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Propranolol: pooled Michaelis-Menten parameters and the effect of input rate on bioavailability.
    Wagner JG
    Clin Pharmacol Ther; 1985 May; 37(5):481-7. PubMed ID: 3987171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioavailability of 14C-sulpiride in dogs.
    Alam AS; Imondi AR; Udinsky J; Hagerman LM
    Arch Int Pharmacodyn Ther; 1979 Nov; 242(1):4-13. PubMed ID: 543747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct measurement of propranolol bioavailability during accumulation to steady-state.
    Wood AJ; Carr K; Vestal RE; Belcher S; Wilkinson GR; Shand DG
    Br J Clin Pharmacol; 1978 Oct; 6(4):345-50. PubMed ID: 698031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological determinants of propranolol disposition in man.
    Kornhauser DM; Wood AJ; Vestal RE; Wilkinson GR; Branch RA; Shand DG
    Clin Pharmacol Ther; 1978 Feb; 23(2):165-74. PubMed ID: 620476
    [No Abstract]   [Full Text] [Related]  

  • 39. Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man.
    Cid E; Mella F; Lucchini L; Cárcamo M; Monasterio J
    Biopharm Drug Dispos; 1986; 7(6):559-66. PubMed ID: 3828485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade.
    Wilson TW; Firor WB; Johnson GE; Holmes GI; Tsianco MC; Huber PB; Davies RO
    Clin Pharmacol Ther; 1982 Dec; 32(6):676-85. PubMed ID: 7140133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.